Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
28347 | 209 | 32.8 | 90% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
6 | 4 | GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY | 1371034 |
531 | 3 | MESOTHELIOMA//ASBESTOS//MALIGNANT MESOTHELIOMA | 19648 |
1763 | 2 | MESOTHELIOMA//MALIGNANT PLEURAL MESOTHELIOMA//MALIGNANT MESOTHELIOMA | 6423 |
28347 | 1 | MESOTHELIN//ERC MESOTHELIN//MORAB 009 | 209 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | MESOTHELIN | authKW | 5295922 | 39% | 45% | 81 |
2 | ERC MESOTHELIN | authKW | 730512 | 2% | 100% | 5 |
3 | MORAB 009 | authKW | 608758 | 2% | 83% | 5 |
4 | SS1P | authKW | 521792 | 2% | 71% | 5 |
5 | LUMINAL MEMBRANE EXPRESSION | authKW | 438307 | 1% | 100% | 3 |
6 | AMATUXIMAB | authKW | 328729 | 1% | 75% | 3 |
7 | ANTIBODY THER Y UNIT | address | 292205 | 1% | 100% | 2 |
8 | CELL SURVIVAL PROLIFERATION | authKW | 292205 | 1% | 100% | 2 |
9 | HUMAN MESOTHELIN | authKW | 194802 | 1% | 67% | 2 |
10 | N ERC MESOTHELIN | authKW | 194802 | 1% | 67% | 2 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 2993 | 61% | 0% | 128 |
2 | Pathology | 190 | 9% | 0% | 19 |
3 | Medicine, Research & Experimental | 86 | 9% | 0% | 18 |
4 | Medical Laboratory Technology | 73 | 3% | 0% | 7 |
5 | Anatomy & Morphology | 33 | 2% | 0% | 4 |
6 | Biochemistry & Molecular Biology | 11 | 11% | 0% | 23 |
7 | Respiratory System | 10 | 2% | 0% | 5 |
8 | Genetics & Heredity | 10 | 4% | 0% | 9 |
9 | Immunology | 7 | 5% | 0% | 10 |
10 | Pharmacology & Pharmacy | 7 | 6% | 0% | 13 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ANTIBODY THER Y UNIT | 292205 | 1% | 100% | 2 |
2 | FORENS MED OCCUPAT MED MED PSYCHOL CRIMINO | 146102 | 0% | 100% | 1 |
3 | INTERDISCIPLINARY MED PALLIAT CARE NURSING | 146102 | 0% | 100% | 1 |
4 | INTERNAL MED 1SECT MOL GI ONCOL | 146102 | 0% | 100% | 1 |
5 | MOL DIAGNOST PROGARM | 146102 | 0% | 100% | 1 |
6 | PALLIAT CARE INTERDISCIPLINARY | 146102 | 0% | 100% | 1 |
7 | SOLID TUMOR IMMUNOTHER Y SECT | 146102 | 0% | 100% | 1 |
8 | SWEDISH HOSP TUMOR | 146102 | 0% | 100% | 1 |
9 | UMR MATRICE EXTRACELLULAIRE DYNAM CELLULAIRE 73 | 146102 | 0% | 100% | 1 |
10 | VIVIAN L SMITH NEUROSUR | 146102 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | MOLECULAR CANCER THERAPEUTICS | 3583 | 5% | 0% | 10 |
2 | CLINICAL CANCER RESEARCH | 3548 | 9% | 0% | 19 |
3 | CANCER SCIENCE | 3351 | 4% | 0% | 9 |
4 | JOURNAL OF CANCER | 1752 | 1% | 0% | 3 |
5 | APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY | 1568 | 2% | 0% | 4 |
6 | GENE THERAPY | 591 | 2% | 0% | 4 |
7 | JOURNAL OF BIOMEDICAL NANOTECHNOLOGY | 391 | 1% | 0% | 2 |
8 | IDRUGS | 390 | 0% | 0% | 1 |
9 | INTERNATIONAL JOURNAL OF CANCER | 345 | 3% | 0% | 7 |
10 | JOURNAL OF IMMUNOTHERAPY | 344 | 1% | 0% | 2 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | MESOTHELIN | 5295922 | 39% | 45% | 81 | Search MESOTHELIN | Search MESOTHELIN |
2 | ERC MESOTHELIN | 730512 | 2% | 100% | 5 | Search ERC+MESOTHELIN | Search ERC+MESOTHELIN |
3 | MORAB 009 | 608758 | 2% | 83% | 5 | Search MORAB+009 | Search MORAB+009 |
4 | SS1P | 521792 | 2% | 71% | 5 | Search SS1P | Search SS1P |
5 | LUMINAL MEMBRANE EXPRESSION | 438307 | 1% | 100% | 3 | Search LUMINAL+MEMBRANE+EXPRESSION | Search LUMINAL+MEMBRANE+EXPRESSION |
6 | AMATUXIMAB | 328729 | 1% | 75% | 3 | Search AMATUXIMAB | Search AMATUXIMAB |
7 | CELL SURVIVAL PROLIFERATION | 292205 | 1% | 100% | 2 | Search CELL+SURVIVAL+PROLIFERATION | Search CELL+SURVIVAL+PROLIFERATION |
8 | HUMAN MESOTHELIN | 194802 | 1% | 67% | 2 | Search HUMAN+MESOTHELIN | Search HUMAN+MESOTHELIN |
9 | N ERC MESOTHELIN | 194802 | 1% | 67% | 2 | Search N+ERC+MESOTHELIN | Search N+ERC+MESOTHELIN |
10 | ADOPTIVE SERUM TRANSFER | 146102 | 0% | 100% | 1 | Search ADOPTIVE+SERUM+TRANSFER | Search ADOPTIVE+SERUM+TRANSFER |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | HASSAN, R , THOMAS, A , ALEWINE, C , LE, DT , JAFFEE, EM , PASTAN, I , (2016) MESOTHELIN IMMUNOTHERAPY FOR CANCER: READY FOR PRIME TIME?.JOURNAL OF CLINICAL ONCOLOGY. VOL. 34. ISSUE 34. P. 4171 -+ | 57 | 70% | 0 |
2 | TANG, ZW , QIAN, M , HO, M , (2013) THE ROLE OF MESOTHELIN IN TUMOR PROGRESSION AND TARGETED THERAPY.ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. VOL. 13. ISSUE 2. P. 276-280 | 32 | 84% | 29 |
3 | BAYOGLU, IV , KUCUKZEYBEK, BB , KUCUKZEYBEK, Y , VAROL, U , YILDIZ, I , ALACACIOGLU, A , AKYOL, M , DEMIR, L , DIRICAN, A , YILDIZ, Y , ET AL (2015) PROGNOSTIC VALUE OF MESOTHELIN EXPRESSION IN PATIENTS WITH TRIPLE NEGATIVE AND HER2-POSITIVE BREAST CANCERS.BIOMEDICINE & PHARMACOTHERAPY. VOL. 70. ISSUE . P. 190 -195 | 28 | 82% | 0 |
4 | PASTAN, I , HASSAN, R , (2014) DISCOVERY OF MESOTHELIN AND EXPLOITING IT AS A TARGET FOR IMMUNOTHERAPY.CANCER RESEARCH. VOL. 74. ISSUE 11. P. 2907-2912 | 26 | 65% | 31 |
5 | EINAMA, T , HOMMA, S , KAMACHI, H , KAWAMATA, F , TAKAHASHI, K , TAKAHASHI, N , TANIGUCHI, M , KAMIYAMA, T , FURUKAWA, H , MATSUNO, Y , ET AL (2012) LUMINAL MEMBRANE EXPRESSION OF MESOTHELIN IS A PROMINENT POOR PROGNOSTIC FACTOR FOR GASTRIC CANCER.BRITISH JOURNAL OF CANCER. VOL. 107. ISSUE 1. P. 137-142 | 21 | 95% | 18 |
6 | KOBAYASHI, K , SASAKI, T , TAKENAKA, F , YAKUSHIJI, H , FUJII, Y , KISHI, Y , KITA, S , SHEN, LH , KUMON, H , MATSUURA, E , (2015) A NOVEL PET IMAGING USING CU-64-LABELED MONOCLONAL ANTIBODY AGAINST MESOTHELIN COMMONLY EXPRESSED ON CANCER CELLS.JOURNAL OF IMMUNOLOGY RESEARCH. VOL. . ISSUE . P. - | 30 | 67% | 0 |
7 | HASSAN, R , HO, M , (2008) MESOTHELIN TARGETED CANCER IMMUNOTHERAPY.EUROPEAN JOURNAL OF CANCER. VOL. 44. ISSUE 1. P. 46-53 | 25 | 63% | 122 |
8 | ZHANG, JL , BERA, TK , LIU, WH , DU, X , ALEWINE, C , HASSAN, R , PASTAN, I , (2014) MEGAKARYOCYTIC POTENTIATING FACTOR AND MATURE MESOTHELIN STIMULATE THE GROWTH OF A LUNG CANCER CELL LINE IN THE PERITONEAL CAVITY OF MICE.PLOS ONE. VOL. 9. ISSUE 8. P. - | 17 | 100% | 0 |
9 | KAWAMATA, F , KAMACHI, H , EINAMA, T , HOMMA, S , TAHARA, M , MIYAZAKI, M , TANAKA, S , KAMIYAMA, T , NISHIHARA, H , TAKETOMI, A , ET AL (2012) INTRACELLULAR LOCALIZATION OF MESOTHELIN PREDICTS PATIENT PROGNOSIS OF EXTRAHEPATIC BILE DUCT CANCER.INTERNATIONAL JOURNAL OF ONCOLOGY. VOL. 41. ISSUE 6. P. 2109 -2118 | 24 | 71% | 8 |
10 | KELLY, RJ , SHARON, E , PASTAN, I , HASSAN, R , (2012) MESOTHELIN-TARGETED AGENTS IN CLINICAL TRIALS AND IN PRECLINICAL DEVELOPMENT.MOLECULAR CANCER THERAPEUTICS. VOL. 11. ISSUE 3. P. 517-525 | 26 | 58% | 33 |
Classes with closest relation at Level 1 |